z-logo
Premium
Advances in the enantioseparation of second‐generation antidepressant drugs by electrodriven methods
Author(s) -
Mandrioli Roberto,
Raggi Maria A.
Publication year - 2006
Publication title -
electrophoresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 158
eISSN - 1522-2683
pISSN - 0173-0835
DOI - 10.1002/elps.200500297
Subject(s) - reboxetine , milnacipran , venlafaxine , sertraline , pharmacology , mirtazapine , antidepressant , citalopram , fluoxetine , duloxetine , reuptake inhibitor , enantiomer , chemistry , reuptake , serotonin , medicine , psychiatry , stereochemistry , biochemistry , anxiety , receptor , alternative medicine , pathology
Abstract Stereochemistry is steadily increasing in importance in the development of new drugs, and the availability of pure enantiomer drugs can make therapy safer and more efficacious. In particular, almost all second‐generation antidepressant drugs possess one or more chiral centres; however, only some of them are administered as single enantiomers. A fundamental part of the quality control of pharmaceutical formulations is the determination of enantiomeric excess and enantiomeric purity; this is also important for the therapeutic drug monitoring of depressed patients. For this purpose, efficient and reliable analytical methods are needed and electrodriven techniques (most of all CE, CEC and MEKC) are very efficient and inexpensive candidates for the role. In this review, the enantioselective electrodriven methods available for the analysis of second‐generation antidepressant are presented and discussed. In particular, the following pharmacological classes of antidepressants will be considered: selective serotonin reuptake inhibitors (fluoxetine, citalopram, paroxetine, sertraline); norepinephrine reuptake inhibitors (reboxetine); serotonin and norepinephrine reuptake inhibitors (venlafaxine, milnacipran, duloxetine); and noradrenergic and specific serotonergic antidepressants (mirtazapine).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here